Release Date: 02/08/18 17:15 Summary: Change in substantial holding - bidder now has 95.61% Price Sensitive: No Download Document 146.46KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%